Overview
Cervical cancer is a significant cause of morbidity and mortality among women worldwide. Radiotherapy, in combination with chemotherapy or as a standalone treatment, is an effective treatment option for cervical cancer. However, traditional radiotherapy has its limitations, such as the potential for damage to surrounding healthy tissues. Stereotactic Body RadioTherapy (SBRT) is a newer radiotherapy technique that delivers high doses of radiation to the tumor with minimal damage to the surrounding tissues. This study aims to evaluate the safety of Stereotactic Body RadioTherapy to involved node in cervical cancer.
Description
The goal of this observational study is to compare the safety profile of Stereotactic Body Radiotherapy Boost vs Simultaneous Integrated Boost to pelvic nodes among patients with Stage III-C carcinoma cervix by assessing the acute GI and GU toxicity (\>Grade 3 GI/GU toxicity) within 30 days of completion of treatment.
Eligibility
Inclusion Criteria:
- Patients with stage IIIC cervical cancer
- No previous pelvic radiation therapy or surgery
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
Exclusion Criteria:
- Patients with stage I or stage II or stage IV disease.
- Patients with prior malignancies or active autoimmune diseases
- Uncontrolled medical comorbidity
